18April

Red Cross and Novo Nordisk announce ground-breaking partnership to tackle chron ... Read more

05April

Novo Nordisk obtains exclusive worldwide licence to EpiDestiny's sickle cell dis ... Read more

26March

FDA approves inclusion of data on cardiovascular outcomes and severe hypoglycaem ... Read more

23March

Ozempic® approved in Japan for the treatment of type 2 diabetes ... Read more

16April

Novo Nordisk A/S - Share repurchase programme ... Read more

09April

Novo Nordisk A/S - Share repurchase programme ... Read more

03April

Status regarding Novo Nordisk's holding of its own shares (31 March 2018) ... Read more

03April

Novo Nordisk A/S - Share repurchase programme ... Read more

02May

Financial statement for the first three months of 2018,

01July

Silent period,

08August

Financial statement for the first six months of 2018,

01October

Silent period,

 

 

 

Investors

 
Share information


Take an advanced view of the Novo Nordisk share

 
Annual Report 2017 


Click here to find further information

 
FY 2017 financial results


Novo Nordisk at a glance


Private shareholders


See relevant content for private investors



IR material


Download relevant Investor Relations material



Contacts



Subscriptions


Sign up to receive company announcements.


Ozempic® US approval


Link to conference call and presentation